Mode
Text Size
Log in / Sign up
Phase 2 Completed N=66 Randomized Quadruple-blind Treatment

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Source: ClinicalTrials.gov NCT00629239 ↗
Enrolled (actual)
66
Serious AEs
3.1%
Results posted
Dec 2010
Primary outcomePrimary: Number of Patients Experiencing Adverse Events — 22; 27 Participants

Summary

The purpose of this study is to see if treatment with AZD4818 for four weeks is tolerable, safe and effective in treating COPD and, if so, how it compares with placebo.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients Experiencing Adverse Events
22; 27
SECONDARY
Forced Expiratory Volume 1 (FEV1)
-0.083; -0.149
SECONDARY
Forced Vital Capacity (FVC)
-0.044; -0.240
SECONDARY
Vital Capacity (VC)
-0.022; -0.022
SECONDARY
Inspiratory Capacity (IC)
-0.117; -0.038
SECONDARY
Forced Expiratory Flow (FEF) 25%-75%
-0.027; 0.006
SECONDARY
Peak Expiratory Flow (PEF) Morning
-9.10; -4.47
SECONDARY
Peak Expiratory Flow (PEF) Evening
-12.4; -1.90
SECONDARY
The Clinical COPD ( Chronic Obstructive Pulmonary Disease) Questionnaire (CCQ) Total
0.250; 0.044
SECONDARY
Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Breathlessness
0.159; -0.007
SECONDARY
Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Chest Tightness
0.170; 0.024
SECONDARY
Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Cough Score
0.064; -0.103
SECONDARY
Chronic Obstructive Pulmonary Disease (COPD) Symptoms, Sleep Score
0.085; 0.000
SECONDARY
6-minute Walk Test
-8.67; -6.67

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of COPD, with symptoms for more than 1 year
  • Current or ex-smokers with a smoking history of at least 10 pack-years (1 pack-year=20 cigarettes/day for 1 year)
  • Lung function (FEV1) 40 to 80% of the predicted normal value after using a short acting bronchodilator

Exclusion Criteria

  • Clinical suspicion of active tuberculosis
  • Any current clinically significant respiratory tract disorder other than COPD
  • History of current clinically relevant arrhythmia, heart block, ECG abnormalities, or unstable angina
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00629239). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search